180 Life Sciences Corp. ATNF
We take great care to ensure that the data presented and summarized in this overview for 180 Life Sciences Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ATNF
Top Purchases
Top Sells
About ATNF
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Insider Transactions at ATNF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2025
|
Ryan Lewis Smith Director |
BUY
Bona fide gift
|
Indirect |
16,718
+50.0%
|
-
|
|
Dec 01
2025
|
Ryan Lewis Smith Director |
SELL
Bona fide gift
|
Direct |
16,718
-100.0%
|
-
|
|
Nov 14
2025
|
Mc Andrew Rudisill Chief Executive Officer |
BUY
Bona fide gift
|
Indirect |
370,000
+47.12%
|
-
|
|
Nov 14
2025
|
Mc Andrew Rudisill Chief Executive Officer |
SELL
Bona fide gift
|
Direct |
410,865
-37.58%
|
-
|
|
Nov 14
2025
|
Ryan Lewis Smith Director |
BUY
Bona fide gift
|
Indirect |
267,137
+50.0%
|
-
|
|
Nov 14
2025
|
Ryan Lewis Smith Director |
SELL
Bona fide gift
|
Direct |
267,137
-36.71%
|
-
|
|
Nov 14
2025
|
Andrew P Suckling Director |
BUY
Bona fide gift
|
Indirect |
149,020
+50.0%
|
-
|
|
Nov 14
2025
|
Andrew P Suckling Director |
SELL
Bona fide gift
|
Direct |
149,020
-50.0%
|
-
|
|
Nov 14
2025
|
Crystal Jane Heter Director |
BUY
Bona fide gift
|
Indirect |
182,742
+50.0%
|
-
|
|
Nov 14
2025
|
Crystal Jane Heter Director |
SELL
Bona fide gift
|
Direct |
182,742
-50.0%
|
-
|
|
Nov 14
2025
|
Jason Griffin New Director |
BUY
Bona fide gift
|
Indirect |
218,456
+50.0%
|
-
|
|
Nov 14
2025
|
Jason Griffin New Director |
SELL
Bona fide gift
|
Direct |
218,456
-30.74%
|
-
|
|
Nov 12
2025
|
John Tazewell Saunders Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,447
-21.45%
|
-
|
|
Nov 12
2025
|
John Tazewell Saunders Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,312
+50.0%
|
-
|
|
Nov 12
2025
|
Mc Andrew Rudisill Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
271,635
-19.9%
|
-
|
|
Nov 12
2025
|
Mc Andrew Rudisill Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,365,000
+50.0%
|
-
|
|
Nov 12
2025
|
Ryan Lewis Smith Director |
SELL
Payment of exercise price or tax liability
|
Direct |
176,613
-19.53%
|
-
|
|
Nov 12
2025
|
Ryan Lewis Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
887,500
+49.53%
|
-
|
|
Nov 12
2025
|
Andrew P Suckling Director |
SELL
Payment of exercise price or tax liability
|
Direct |
175,854
-27.07%
|
-
|
|
Nov 12
2025
|
Andrew P Suckling Director |
BUY
Grant, award, or other acquisition
|
Direct |
649,748
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 5.45M shares |
|---|---|
| Bona fide gift | 1.2M shares |
| Other acquisition or disposition | 1.72M shares |
| Conversion of derivative security | 1.32M shares |
| Exercise of in-the-money or at-the-money derivatives securities | 3M shares |
| Payment of exercise price or tax liability | 1.05M shares |
|---|---|
| Bona fide gift | 1.24M shares |
| Other acquisition or disposition | 360K shares |
| Open market or private sale | 3M shares |